PaxMedica Completes HAT-301 Registrational Trial For PAX-101; Top Line Results Planned For Release July 2023
Portfolio Pulse from Benzinga Newsdesk
PaxMedica has completed its HAT-301 registrational trial for PAX-101, with top line results expected to be released in July 2023.
June 01, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PaxMedica's completion of the HAT-301 trial for PAX-101 may positively impact its stock price in the short term.
The completion of the HAT-301 trial for PAX-101 is a significant milestone for PaxMedica, as it brings the company closer to potentially receiving regulatory approval for the drug. This news may be seen as a positive development by investors, leading to a short-term increase in the stock price of PXMD.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100